Rose-Marie Amini – Haematopathology
Our overarching goal is to improve therapy and survival for patients with malignant lymphoma. The work focuses on identifying new markers that can be used for diagnosis and prognosis for lymphoma patients. We also want to increase the knowledge about disease development and to define the role of the immune system’s own cells in lymphoma development and tumour growth.
Each year approximately 2000 people in Sweden are diagnosed with malignant lymphoma. This is a type of cancer in the lymph nodes where lymphocytes, one of the cell types in the immune system, give rise to the disease. Malignant lymphoma is a heterogeneous group of diseases and more than 100 specific subtypes of lymphoma can be identified.
In the last 20 years the development of both diagnostics and therapies for malignant lymphoma has been very successful but there is still a need for enhanced knowledge about which genetic aberrations are present in different kinds of lymphoma. It is also important to study the microenvironment in the tumour to determine how cells that are not tumour cells, e.g. immune-regulatory cells, affect disease development and potential therapy resistance. These might also be targets for new, specific treatment strategies.
Our research focuses on three main objectives:
- To identify new diagnostic, prognostice and predictive markers for malignant lymphoma. We study both indolent B-cell lymphoma such a marginal zone lymphoma, and clinically very aggressive forms of B and T-cell lymphoma.
- To study various markers and genetic aberration that are relevant for lymphoma development and disease progression. We analyse clinically well characterised patient cohorts in relation to given treatment, known clinical prognosis factors and survival.
- To increase the knowledge about disease progression for malignant lymphoma and the role of immune regulatory cells in the immune system for lymphoma development and tumour growth.
The research is performed in close collaboration with Gunilla Enblad's group at IGP.
Group members
Publications
Part of Leukemia, p. 438-441, 2024
Genetic Characterization of Primary Mediastinal B-Cell Lymphoma: Pathogenesis and Patient Outcomes
Part of Journal of Clinical Oncology, p. 452-466, 2024
ADAR1-mediated RNA editing promotes B cell lymphomagenesis
Part of iScience, 2023
Managing leukemia patients via liquid biopsy and super rolling circle amplification (superRCA)
Part of Journal of Internal Medicine, p. 228-237, 2023
Part of Cancers, 2023
Part of Clinical Cancer Research, p. 4139-4152, 2023
- DOI for Single-Cell RNA Analysis Reveals Cell-Intrinsic Functions of CAR T Cells Correlating with Response in a Phase II Study of Lymphoma Patients
- Download full text (pdf) of Single-Cell RNA Analysis Reveals Cell-Intrinsic Functions of CAR T Cells Correlating with Response in a Phase II Study of Lymphoma Patients
Part of Blood Advances, p. 5304-5313, 2023
Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma
Part of Journal of Clinical Investigation, 2023
Checkpoint CD47 expression in classical Hodgkin lymphoma
Part of British Journal of Haematology, p. 580-589, 2022
Immune-Proteome Profiling in Classical Hodgkin Lymphoma Tumor Diagnostic Tissue
Part of Cancers, 2022
Part of Diagnostics, 2022
Outcome in PCNSL patients and its association with PD-L1+leukocytes in the tumor microenvironment
Part of Acta Oncologica, p. 824-829, 2022
The dual role of CD70 in B‐cell lymphomagenesis
Part of Clinical and Translational Medicine, 2022
Part of Genes, Chromosomes and Cancer, p. 27-36, 2022
Part of British Journal of Haematology, p. 520-531, 2021
- DOI for Infiltration of CD163-, PD-L1-and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors
- Download full text (pdf) of Infiltration of CD163-, PD-L1-and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors
Part of Acta Oncologica, p. 531-538, 2021
Revisiting IL-6 expression in the tumor microenvironment of classical Hodgkin lymphoma
Part of Blood Advances, p. 1671-1681, 2021
Part of British Journal of Haematology, p. 568-579, 2021
Part of Blood, p. 216-231, 2021
CD30 expression and survival in posttransplant lymphoproliferative disorders
Part of Acta Oncologica, p. 673-680, 2020
Part of American Journal of Hematology, p. 57-67, 2020
- DOI for Cell-of-origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B-cell lymphoma
- Download full text (pdf) of Cell-of-origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B-cell lymphoma
Clonal hematopoiesis in patients with high-grade B-cell lymphoma is associated with inferior outcome
Part of American Journal of Hematology, 2020
Marginal zone lymphoma expression of histidine-rich glycoprotein correlates with improved survival
Part of eJHaem, p. 199-207, 2020
Part of Immunobiology, 2020
Prognostic impact of abdominal lymph node involvement in diffuse large B-cell lymphoma
Part of European Journal of Haematology, p. 207-213, 2020
Altered profile of immune regulatory cells in the peripheral blood of lymphoma patients
Part of BMC Cancer, 2019
Part of Journal of Pathology, p. 416-421, 2019
Part of British Journal of Haematology, p. 431-439, 2019
Part of British Journal of Haematology, p. 192-201, 2019
Part of EBioMedicine, p. 150-158, 2019
Part of Clinical Cancer Research, p. 5895-5901, 2018
A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia
Part of Clinical Cancer Research, p. 6185-6194, 2018
Part of European Journal of Haematology, p. 88-97, 2018
Part of PLOS ONE, 2018
Refractory chronic "ITP": When platelet size matters
Part of Clinical Case Reports, p. 1779-1780, 2018
Part of Acta Oncologica, p. 106-109, 2017
Estrogen receptor beta 1 in diffuse large B-cell lymphoma growth and as a prognostic biomarker
Part of Leukemia and Lymphoma, p. 418-427, 2017
Part of Blood Advances, p. 1427-1439, 2017
KIT signaling is dispensable for human mast cell progenitor development
Part of Blood, p. 1785-1794, 2017
Part of Läkartidningen, 2017
Part of Acta Oncologica, p. 599-607, 2017
Part of Acta Oncologica, p. 1126-1131, 2016
Chromosome 11q23 aberrations activating FOXR1 in B-cell lymphoma
Part of Blood Cancer Journal, 2016
Diffuse Large B Cell Lymphoma Cell Line U2946: Model for MCL1 Inhibitor Testing
Part of PLOS ONE, 2016
Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma
Part of Blood, p. 2666-2670, 2016
Part of European Journal of Haematology, p. 430-438, 2016
- DOI for The role of tumour-infiltrating eosinophils, mast cells and macrophages in Classical and Nodular Lymphocyte Predominant Hodgkin Lymphoma in children
- Download full text (pdf) of The role of tumour-infiltrating eosinophils, mast cells and macrophages in Classical and Nodular Lymphocyte Predominant Hodgkin Lymphoma in children
Autoimmune and Atopic Disorders and Risk of Classical Hodgkin Lymphoma
Part of American Journal of Epidemiology, p. 624-632, 2015
Part of Acta Oncologica, p. 538-544, 2015
Part of Blood, 2015
Part of Cancer Research, 2015
FOXR1 Activation in B-Cell Lymphoma
Part of Blood, 2015
Part of Medical Oncology, 2015
The prognostic role of HER2 expression in ductal breast carcinoma in situ
Part of Cancer Research, 2015
Part of BMC Cancer, 2015
Part of Blood, 2015
Part of Cancer Research, 2015
Part of International Journal of Breast Cancer, 2014
Part of European Journal of Haematology, p. 377-381, 2014
Part of PLOS ONE, 2014
- DOI for Human cytomegalovirus tegument protein pp65 is detected in all intra- and extra-axial brain tumours independent of the tumour type or grade
- Download full text (pdf) of Human cytomegalovirus tegument protein pp65 is detected in all intra- and extra-axial brain tumours independent of the tumour type or grade
Part of Haematologica, p. 279-280, 2014
Part of European Journal of Haematology, p. 500-508, 2014
Part of Annals of Surgical Oncology, p. 2911-2919, 2014
Part of International Journal of Breast Cancer, 2013
High expression of microRNA-200c predicts poor clinical outcome in diffuse large B-cell lymphoma
Part of Oncology Reports, p. 720-724, 2013
Part of International Journal of Hematologic Oncology, p. 391-396, 2013
Part of International Journal of Hematology, p. 465-471, 2013
Part of BMC Cancer, p. 512, 2013
Molecular subtyping of male breast cancer using alternative definitions and its prognostic impact
Part of Acta Oncologica, p. 102-109, 2013
Role of microRNAs and microRNA machinery in the pathogenesis of diffuse large B-cell lymphoma
Part of Blood Cancer Journal, 2013
U-2932: two clones in one cell line, a tool for the study of clonal evolution
Part of Leukemia, p. 1155-1164, 2013
Part of Journal of the National Cancer Institute, p. 240-253, 2012
Inflammatory cells in node-negative breast cancer
Part of Acta Oncologica, p. 680-686, 2012
Part of Histopathology, p. 26-32, 2012
Part of European Journal of Haematology, p. 208-216, 2011
Part of Leukemia Research, p. 438-443, 2011
The effect of Eosinophil cationic protein (ECP) on Hodgkin lymphoma cell lines
Part of Experimental Hematology, p. 850-858, 2011
Part of International Journal of Cancer, p. 961-967, 2010
Part of Läkartidningen, p. 672-675, 2010
Part of BMC Cancer, p. 653, 2010
Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer
Part of Molecular Oncology, p. 357-368, 2010
Neuroendocrine markers are expressed in human mammary glands
Part of Regulatory Peptides, p. 68-74, 2010
Part of British Journal of Haematology, p. 683-684, 2009
Cyclin A is a proliferative marker with good prognostic value in node-negative breast cancer
Part of Cancer Epidemiology, Biomarkers and Prevention, p. 2501-2506, 2009
Part of Breast Cancer Research and Treatment, p. 75-82, 2009
High cyclin B1 expression is associated with poor survival in breast cancer
Part of British Journal of Cancer, p. 1055-60, 2009
Part of Leukemia Research, p. 60-66, 2009
Part of Histopathology, p. 773-775, 2008
Part of Clinical Cancer Research, p. 1976-83, 2008
Establishment of a cell line from a chemotherapy resistant diffuse large B-cell lymphoma
Part of Leukemia and Lymphoma, p. 1038-1041, 2007
Genomic imbalances during transformation from follicular lymphoma to diffuse large B-cell lymphoma
Part of Modern Pathology, p. 63-75, 2007
Ki67 and cyclin A as prognostic factors in early breast cancer: What are the optimal cut-off values?
Part of Histopathology, p. 491-498, 2007
Mast cell infiltration is a favourable prognostic factor in diffuse large B-cell lymphoma
Part of British Journal of Haematology, p. 68-71, 2007
Mast cells and eosinophils in invasive breast carcinoma
Part of BMC Cancer, p. 165, 2007
Part of Blood, p. 4930-4935, 2007
IL-9 expression contributes to the cellular composition in Hodgkin lymphoma
Part of European Journal of Haematology, p. 278-283, 2006
Part of British Journal of Cancer, p. 1697-1702, 2006
Angiogenesis and mast cells in Hodgkin lymphoma
Part of Leukemia, p. 2360-2362, 2005
Part of Leukemia and Lymphoma, p. 2179-2189, 2002
A population-based study of the outcome for patients with first relapse of Hodgkin lymphoma
Part of European Journal of Haematology, p. 225-232, 2002
Relapsed Hodgkin's lymphoma: immunostaining patterns in relation to survival
Part of Leukemia and Lymphoma, p. 1253-1260, 2002